openFDA
Cure8 regulatory brief
Why This Matters
FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib with other immunosuppressive drugs.
Who Should Pay Attention
Adults with ulcerative colitis or other approved indications considering or taking tofacitinib; clinicians who prescribe or monitor JAK inhibitors; patients on biologics or potent immunosuppressants.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
The document is an official FDA-linked drug label update, not a research paper. It summarizes indications, limitations of use, and safety warnings that can affect prescribing and monitoring.
The boxed warning highlights risks already associated with JAK inhibitors (infections, malignancy, CV events, thrombosis) and reiterates that tofacitinib should not be used with certain other immunosuppressants or biologic therapies.
If you take or prescribe tofacitinib for ulcerative colitis or another approved condition, important takeaways are that clinicians should screen for latent TB before starting therapy, watch closely for signs of infection during treatment, and avoid combining with specified biologics or potent immunosuppressants.
Dose restrictions (e.g., recommendation against 10 mg twice daily for several non-UC indications) are noted in the label. Keep discussions about whether to start, stop, or change tofacitinib with your prescribing clinician; this label is intended to inform clinical decisions and monitoring rather than provide individual medical advice.
Keep In Mind
This entry is the official prescribing information (regulatory drug label). It summarizes approved uses and safety warnings based on regulatory review. It does not present new trial results or comparative effectiveness data beyond the label language.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorZydus Pharmaceuticals USA Inc.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 30, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TOFACITINIB FDA label update (2026-07-06)
The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.
A Case of Elderly-Onset Ulcerative Colitis with Large-Vessel Giant Cell Arteritis Treated Successfully with Tofocitinib.
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
TOFACITINIB FDA label update (2026-07-31)
This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.